Town & Country Bank & Trust CO dba First Bankers Trust CO Sells 75 Shares of Amgen Inc. (NASDAQ:AMGN)

Town & Country Bank & Trust CO dba First Bankers Trust CO lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 4.6% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,545 shares of the medical research company’s stock after selling 75 shares during the quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Amgen were worth $439,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in AMGN. Bank of Nova Scotia increased its holdings in Amgen by 11.4% in the third quarter. Bank of Nova Scotia now owns 54,628 shares of the medical research company’s stock valued at $14,682,000 after purchasing an additional 5,609 shares during the last quarter. CWA Asset Management Group LLC boosted its stake in Amgen by 26.9% during the 3rd quarter. CWA Asset Management Group LLC now owns 2,334 shares of the medical research company’s stock worth $627,000 after acquiring an additional 495 shares during the last quarter. Teza Capital Management LLC grew its holdings in Amgen by 448.3% during the third quarter. Teza Capital Management LLC now owns 5,340 shares of the medical research company’s stock valued at $1,435,000 after purchasing an additional 4,366 shares during the period. Sherbrooke Park Advisers LLC acquired a new stake in Amgen in the third quarter worth $411,000. Finally, Fred Alger Management LLC boosted its position in shares of Amgen by 963.8% during the third quarter. Fred Alger Management LLC now owns 95,071 shares of the medical research company’s stock worth $25,551,000 after purchasing an additional 86,134 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the subject of a number of recent analyst reports. Mizuho upped their price objective on shares of Amgen from $223.00 to $235.00 and gave the company a “neutral” rating in a research report on Thursday, May 9th. BMO Capital Markets lifted their price objective on Amgen from $336.00 to $355.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. UBS Group increased their target price on Amgen from $284.00 to $307.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. Royal Bank of Canada lifted their price target on shares of Amgen from $328.00 to $332.00 and gave the company an “outperform” rating in a research note on Friday, June 14th. Finally, Raymond James initiated coverage on shares of Amgen in a research report on Thursday, March 28th. They set a “market perform” rating for the company. Ten research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $307.35.

Amgen Stock Performance

AMGN stock traded down $1.24 during trading hours on Friday, reaching $312.45. The stock had a trading volume of 3,518,174 shares, compared to its average volume of 2,437,626. The stock has a 50-day simple moving average of $301.56 and a 200 day simple moving average of $292.23. Amgen Inc. has a fifty-two week low of $218.44 and a fifty-two week high of $329.72. The stock has a market capitalization of $167.61 billion, a PE ratio of 44.64, a price-to-earnings-growth ratio of 2.82 and a beta of 0.60. The company has a debt-to-equity ratio of 11.96, a current ratio of 1.42 and a quick ratio of 0.98.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.76 by $0.20. The business had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. Amgen’s revenue was up 22.0% on a year-over-year basis. During the same period last year, the business posted $3.98 EPS. Analysts predict that Amgen Inc. will post 19.47 EPS for the current fiscal year.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 2,117 shares of the stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the sale, the senior vice president now owns 9,883 shares in the company, valued at approximately $3,094,268.47. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.69% of the stock is currently owned by corporate insiders.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.